Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Fruquintinib vs BSC in Advanced Salivary Gland Cancer (Japan, DCT-enabled)
jRCT2041250016Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of fruquintinib in salivary gland cancer (SGC) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Centrally assessed progression-free survival (PFS). Started Mar 2025; status: active, not recruiting.
02
Drugs
fruquintinib
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on jRCT2041250016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250016.